You are here

Article Text

Article menu
Download PDFPDF
Letters
PostScript
Hydrocortisone treatment for severe evolving bronchopulmonary dysplasia and cerebral haemodynamics
  1. G Cambonie1,
  2. R Mesnage1,
  3. C Milési1,
  4. A Rideau1,
  5. C Veyrac2,
  6. J-C Picaud1
  1. 1
    Neonatal Intensive Care Unit, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, Montpellier, France
  2. 2
    Department of Pediatric Radiology, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, Montpellier, France
  1. Dr Gilles Cambonie, Unité de Réanimation Néonatale, Pédiatrie II, Hôpital Arnaud de Villeneuve, 371 Avenue du Doyen G. Giraud, 34295 Montpellier Cedex 5, France; g-cambonie{at}chu-montpellier.fr

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the paper by Rademaker et al, in which the authors raised the question of replacing dexamethasone with hydrocortisone to treat severe evolving bronchopulmonary dysplasia (BPD).1 In 2006, a national survey revealed that 91% of French neonatologists used betamethasone for delayed treatment of BPD. From October 2004 to June 2006, we treated 12 infants with betamethasone for severe evolving BPD and observed a pronounced decrease in cerebral blood flow velocities (CBFVs).2 Moreover, a quarter of these patients also …

    View Full Text

    Footnotes

    • Competing interests: None.

    • Ethics approval: The study was approved by the ethics committee of our institution.

    • Patient consent: Parental consent obtained.